Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
DD Ho, AU Neumann, AS Perelson, W Chen… - Nature, 1995 - nature.com
Abstract Treatment of infected patients with ABT-538, an inhibitor of the protease of human
immuno-deficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease …
immuno-deficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease …
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
…, F Boulad, P Poignard, DR Burton, F Pereyra, DD Ho… - Science, 2011 - science.org
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …
[HTML][HTML] Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7
The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end …
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end …
[HTML][HTML] Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
The B.1.1.529/Omicron variant of SARS-CoV-2 was only recently detected in southern Africa,
but its subsequent spread has been extensive, both regionally and globally 1 . It is …
but its subsequent spread has been extensive, both regionally and globally 1 . It is …
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
…, R Brookmeyer, J Gallant, M Markowitz, DD Ho… - Science, 1997 - science.org
The hypothesis that quiescent CD4 + T lymphocytes carrying proviral DNA provide a reservoir
for human immunodeficiency virus–type 1 (HIV-1) in patients on highly active antiretroviral …
for human immunodeficiency virus–type 1 (HIV-1) in patients on highly active antiretroviral …
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
V Simon, DD Ho, QA Karim - The Lancet, 2006 - thelancet.com
The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries
and regions of the world, and is undoubtedly the defining public-health crisis of our time. …
and regions of the world, and is undoubtedly the defining public-health crisis of our time. …
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
…, V Cerundolo, A Hurley, M Markowitz, DD Ho… - Science, 1998 - science.org
Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human
immunodeficiency virus–type 1 (HIV-1) infection, it has not been possible to demonstrate a …
immunodeficiency virus–type 1 (HIV-1) infection, it has not been possible to demonstrate a …
[PDF][PDF] Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization
The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B.1.1.7 and B.…
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B.1.1.7 and B.…
[HTML][HTML] Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic continues,
with devasting consequences for human lives and the global economy 1 , 2 . The discovery …
with devasting consequences for human lives and the global economy 1 , 2 . The discovery …
[HTML][HTML] Extrapulmonary manifestations of COVID-19
…, MSV Elkind, GW Stone, A Schwartz, DD Ho… - Nature medicine, 2020 - nature.com
Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …
also result in several extrapulmonary manifestations. These conditions include thrombotic …